Expanded Newborn Screening to Detect More Diseases, Saving Lives

Newborn screening, a cornerstone of preventative medicine, is poised for significant expansion in Germany in May 2026. This advancement, built on decades of research originating at Heidelberg University Hospital (UKHD), will increase the number of detectable congenital diseases from 19 to 33, potentially saving countless children from severe disabilities and improving their quality of life. The expansion includes screening for congenital vitamin B12 deficiency, homocystinuria, propionic acidemia, and methylmalonic aciduria.

A Legacy of Pioneering Research

The roots of this progress lie in the tireless operate of researchers like Professor Horst Bickel, a pioneer in the treatment of phenylketonuria (PKU). In the 1950s, Bickel developed a specialized diet for managing PKU, a congenital metabolic disorder. He later led the Heidelberg University Hospital’s children’s clinic from 1967 to 1987, championing the introduction of PKU screening as a standard examination for newborns throughout Germany. Heidelberg University Hospital continues to be a central hub for metabolic disease research.

How Newborn Screening Works

Newborn screening (NGS) identifies infants with certain congenital diseases in the first days of life, allowing for early intervention before symptoms develop. Currently, the German NGS program targets 19 diseases that, if left untreated, can lead to organ damage, disability, or even death. The upcoming expansion will increase this to 33 diseases, identifying approximately one in 600 newborns with a treatable condition.

The Role of the Dietmar Hopp Foundation

The Dietmar Hopp Foundation has been instrumental in advancing newborn screening research for the past 25 years, contributing approximately 17 million euros to projects like “NGS2025” and the construction of the Dietmar Hopp Metabolism Center. This support has enabled crucial pilot studies and the development of the infrastructure necessary for expanded screening capabilities.

Specific Diseases Now Included in Screening

• Congenital Vitamin B12 Deficiency: Early diagnosis and vitamin B12 supplementation can prevent neurological developmental issues often caused by maternal deficiency during pregnancy.
• Homocystinuria: A group of diseases characterized by homocysteine buildup, leading to developmental disorders, vision problems, and vascular issues if untreated. Management involves a low-protein diet, vitamins, and medication.
• Propionic Acidemia & Methylmalonic Aciduria: Rare metabolic disorders causing toxic buildup and organ damage. Special diets and medications can mitigate these effects.

Long-Term Benefits Confirmed by Research

A large-scale, long-term study led by Professor Dr. Ulrike Mütze and Professor Dr. Stefan Kölker at the Center for Child and Adolescent Medicine Heidelberg has demonstrated the significant benefits of early diagnosis and treatment through newborn screening. Children diagnosed with congenital metabolic diseases through NGS since 1999 generally grow up symptom-free and exhibit age-appropriate mental development. The study, with a follow-up period of up to 25 years and over 750 participants, provides concrete suggestions for further improving the long-term outcomes for affected individuals.

Looking Ahead

Professor Dr. Georg Friedrich Hoffmann, Medical Director of the Center for Child and Adolescent Medicine and the Screening Laboratory at Heidelberg University Hospital, emphasizes that research into congenital metabolic disorders and early detection methods continues to thrive in Heidelberg. New examination techniques and therapies are under development, promising further expansion and refinement of newborn screening in the years to come. The success of this program exemplifies how sustained funding and dedicated research can have a lasting impact on public health and improve the lives of children and their families.